Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Glioblastoma Vaccines
Researchers from Duke University, Division of Neurosurgery describe findings in glioblastoma vaccines
December 2nd, 2008
Current study results from the report, 'Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines,' have been published. "The epidermal growth factor receptor variant III (EGFRvIII) is a consistent tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms. As such it represents a truly tumor-specific target for antitumor immunotherapy," scientists writing in the Journal of Immunological Methods report. "Although endogenous humoral responses to EGFRvIII have been reported in patients with EGFRvIII-expressing breast cancer, it is not known whether de novo responses can be generated or...
Source: Cancer Weekly (2008-12-02)
|
